Lead Sponsor

Alfasigma S.p.A.

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Males or females who may benefit from filgotinib as judged by the investigator AND who completed a Gilead sponsored filgotinib parent study for RA as outlined below:
•* Have completed GS-US-417-0301, GS-US-417-0302 or GS-US-417-0303 on study drug
•* OR
•* Have completed GS-US-417-0302 on standard of care therapy due to RA non-responder status
•Females of childbearing potential must have a negative pregnancy test prior to first dose of study drug in the long term extension (LTE)
•Females of childbearing potential who engage in heterosexual intercourse must agree to protocol-approved methods of contraception

•Diagnosis of an autoimmune or inflammatory joint disease other than RA, which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator
•Known hypersensitivity to the study drug or its excipients
•Any medical condition which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator

Related studies

NCT07171983 · Rheumatoid Arthritis

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more

NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis